CLDX vs KEYS · rev $7.0M vs P/E 57, rev $4.98B
Celldex Therapeutics Inc (CLDX) versus Keysight Technologies Inc (KEYS) — a side-by-side from cached financials, not a winner call.
Celldex Therapeutics Inc (CLDX) is a biotechnology company listed on US.
Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.
Latest reported CLDX revenue for 2024-12-31 was $7.0M. Revenue was up 2.0% from 2023-12-31 to 2024-12-31. CLDX currently screens at market cap $2.35B.
Latest reported KEYS revenue for 2024-10-31 was $4.98B. Net income was $614.0M. Revenue was down 8.9% from 2023-10-31 to 2024-10-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
CLDX currently screens at market cap $2.35B. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
Not investment advice. Open the CLDX and KEYS stock pages for the full models.
Not investment advice.